Exactly... and only after success in eINDs did FDA
Post# of 148170
(Total Views: 766)
Posted On: 09/06/2020 4:10:08 AM
Exactly... and only after success in eINDs did FDA allow to proceed to the trials...
Otherwise pre-clinical and IND enabling work would have had to be done and the COVID-19 trials miggt not even have started yet.
Also, I was extremely disappointed that NP didn't give him sufficient credit for cancer in the latest interview:
Dr Pestell's theory was that tumor cells must be CCR5 positive - virtually no enrollment.
Dr Patterson disagreed and said only 20% of patients will have CCR5 positive tumor cells, but macrophages around tumors being CCR5 positive will suffice.
With this discovery alone, BP shaped the future of CYDY in cancer!
So nice try by NP to downplay his role, but doesn't really work on those who paid attention...
Fortunately, BP has too much style to play this embarassing little jealously game in public and will continue promoting leronlimab instead of badmouthing people. Though I'd wish he'd publicly correct NP's misleading statements in passing...
Otherwise pre-clinical and IND enabling work would have had to be done and the COVID-19 trials miggt not even have started yet.
Also, I was extremely disappointed that NP didn't give him sufficient credit for cancer in the latest interview:
Dr Pestell's theory was that tumor cells must be CCR5 positive - virtually no enrollment.
Dr Patterson disagreed and said only 20% of patients will have CCR5 positive tumor cells, but macrophages around tumors being CCR5 positive will suffice.
With this discovery alone, BP shaped the future of CYDY in cancer!
So nice try by NP to downplay his role, but doesn't really work on those who paid attention...
Fortunately, BP has too much style to play this embarassing little jealously game in public and will continue promoting leronlimab instead of badmouthing people. Though I'd wish he'd publicly correct NP's misleading statements in passing...
(9)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼